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Abstract 33 
The present study was designed to delineate the immunomodulatory role of histamine 34 
receptors (H1- and H2-) on induction of antibody response to sheep red blood cells 35 
(SRBC), as well as the antibody generation profile, in rabbit system, systemically. The 36 
rabbits in two groups received pheniramine (H1-receptor antagonist) and ranitidine (H2-37 
receptor antagonist), respectively, via intramuscular route and were immunized with 38 
SRBC by intravenously to evaluate suppression or enhancement of antibody responses in 39 
serum. A third, control group, received vehicle and immunized in similar manner. 40 
Histamine released from effector cells (mast cells and basophils) in vivo during 41 
inflammatory reactions could influence a detectable antibody response to SRBC as early 42 
as day 7-postimmunization (post-I), which lasted until day 28- post-I. Pheniramine-43 
treated rabbits had significantly (*P≤ 0.05 and **P≤ 0.01) more suppressed total serum 44 
antibody (IgM + IgG) to SRBC as compared to ranitidine-treated and control rabbits, 45 
while ranitidine-treated rabbits showed different pattern (suppressed or enhanced) during 46 
the whole study period. Ranitidine suppressed total antibody level at day’s 7- and 14- 47 
post-I, and enhanced at days 21- and 28- post-I. IgM suppression at day 7- and 48 
enhancement at days 14-, 21- and 28- post-I, while IgG suppression during whole study 49 
period, as compared to control group was significant (*P≤ 0.05 and **P≤ 0.01) as assessed 50 
by direct hemagglutination assay* and whole SRBC-ELISA method**. Here we report 51 
that histamine receptor type 2 (H2R)-antagonists have a dominant role on 52 
immunosuppression and in immunoregulation of humoral immune responses. Histamine 53 
receptor type 2 (H2R)-antagonists are mainly involved in B cell differentiation and 54 
proliferation over histamine receptor type 1 (H1R)-antagonists. 55 
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Histamine, a biogenic amine is considered not only a mediator of chronic 79 
inflammation and hypersensitivity but also a regulator of several essential events in the 80 
immune response. Histamine regulates dendritic cells, T-lymphocytes, B-lymphocytes, as 81 
well as related antibody isotype responses. Recently, accumulating evidence has 82 
highlighted the importance of histamine receptors in immunomodulation1-9. Histamine 83 
released from mast cells and basophils during inflammatory reactions can modulate 84 
immune response5. Its immunosuppressive and immunomodulatory effects on both 85 
humoral- and cell-mediated immune (HI and CMI, respectively) responses have been 86 
observed.10-11 87 
Histamine receptors have previously been shown to enhance delayed hypersensitivity and 88 
antibody mediated immune responses in many pathological processes regulating several 89 
essential events in allergies and autoimmune diseases in experimental animals, especially 90 
in knock out mice (either H1 or H2 deficient).  The studies evaluating the role with 91 
receptors intact, but blocked by respective antagonists, and especially studying the 92 
immunomodulatory profile over a span of time are lacking in the existing literature. 93 
Moreover, the studies in rabbit model are elementary, and the existing studies have 94 
demonstrated the immunomodulatory role studying only single blood samples taken after 95 
immunizing the animal.  96 
The investigations account for an important regulatory mechanism in the control of 97 
inflammatory functions in immune regulation through effector cells (mast cells and 98 
basophils)-derived histamine, and histamine inverse agonist (histamine antagonist). 99 
Histamine receptor type 1 (H1R) and histamine receptor type 2 (H2R) both belong to the 100 
G-protein-coupled receptor (GPCR) family12-13 however, they trigger different 101 
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biochemical intracellular events upon activation14-15. Jutel et al.3 investigated the H1R-102 
specific antagonist tripelennamine-inhibited histamine binding in Th1 but not in Th2 cells 103 
and demonstrated predominant H1R expression on Th1 cells. Neither the H2R antagonist 104 
(ranitidine) nor the H3R antagonist (clobenpropit) had any impact on histamine binding 105 
to Th1 cells. Rather, H1R and H2R are regulated by specific cytokines present in the 106 
immune system. They demonstrated the expression of H1R on Th1 cells and H2R on Th2 107 
cells by antibodies generated against the H1R and H2R3. 108 
The present study was therefore designed to study the immunomodulatory effects, and 109 
especially the immunoglobulin profile over a period of 28 days, of H1R and H2R 110 
antagonists in rabbit model, systemically. Here we report that histamine enhances total 111 
antibody production by triggering the histamine receptors (HRs), whereas both histamine 112 
receptor type 1 (H1R)-antagonist and histamine receptor type 2 (H2R)-antagonist 113 
positively or negatively regulate the total antibody profile through activation of different 114 
biochemical intracellular signals. 115 
RESULTS 116 
To evaluate the effects of histamine-receptor antagonists on the immunomodulation, 117 
antibody-mediated responses to sheep red blood cells (SRBC) were assessed. Total serum 118 
antibody, total immunoglobulin M (IgM) and total immunoglobulin G (IgG) generation 119 
profiles were studied in vivo in three experimental groups at days 0 [preimmunization 120 
(pre-I)], 7, 14, 21 and 28 [postimmunization (post-I)]. 121 
Profile of total anti-SRBC-antibody production  122 
Total anti-SRBC-antibody titer was determined by a direct haemagglutination assay16. 123 
The results were expressed as mean + S. D. of –log2 titers of each experiment with six 124 
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rabbits.  No antibody response was detected in all three groups (control and drug treated) 125 
at day 0 (pre-I). There was a gradual increase and then slight decrease in total serum 126 
antibody titer over a time span of 28 days in all groups (Fig. 1), and that was found 127 
statistically significant (P≤ 0.05). By day 7- post-I, the antibody titer was significantly 128 
high, however it obtained a peak at day 14, and by days 21- and 28- post-I a gradual 129 
decrease was noticed in all experimental groups; however baseline could not be touched 130 
after 28 days (Fig. 1). H1R-antagonist (pheniramine)-treated rabbits showed significant 131 
(P≤ 0.05) suppression of total anti-SRBC-antibody as opposed to that of H2R-antagonist 132 
(ranitidine)-treated, and control rabbits. Ranitidine-treated rabbits showed slightly 133 
different pattern of initial suppression and later enhancement of anti-SRBC-antibody 134 
production profile during the whole study. Ranitidine significantly (P≤ 0.05) suppressed 135 
total serum anti-SRBC-antibody level at day’s 7- and 14- post-I, and in the later period 136 
enhanced total serum anti-SRBC-antibody levels at day’s 21- and 28- post-I (Fig. 1) as 137 
compared to control rabbits.  138 
Profile of total anti-SRBC IgM production  139 
Anti-SRBC IgM was determined by a direct haemagglutination assay16 and the results 140 
were expressed as –log2 titer ± S.D. as described above. No IgM response was observed 141 
in all three groups (control and drug treated) at day 0- pre-I, however there was an initial 142 
increase and then gradual decrease in serum-IgM titer over time in all groups (Fig. 2). By 143 
day 7- post-I, the IgM titer increased and obtained highest peak at day 14 (but not 144 
observed in control group), and by day’s 21- and 28- post-I there was a gradual decrease 145 
in all experimental groups (Fig. 2) and this was found statistically significant (P≤ 0.05). 146 
H1R-antagonist (pheniramine)-treated rabbits significantly (P≤ 0.05) showed more 147 
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suppression of total anti-SRBC-IgM as compared to H2R-antagonist (ranitidine)-treated 148 
and control rabbits. Similar to total antibody profile, ranitidine-treated rabbits showed 149 
suppression of anti-SRBC-IgM level at day 7- post-I, and then enhanced production of 150 
anti-SRBC-IgM at days 14-, 21- and 28- post-I (Fig. 2) as compared to control rabbits 151 
(P≤ 0.05).  152 
Profile of total anti-SRBC IgG production  153 
The profile of anti-SRBC IgG was studied by direct haemagglutinatin assay using 2-ME 154 
treatmed serum 16 and by whole SRBC-ELISA method17. The observed profiles were 155 
similar by HA and ELISA assays, however, the results were found comparatively more 156 
significant by ELISA (P≤ 0.01) as opposed to HA (P≤ 0.05). Both HIR- antagonist and 157 
H2R- antaonist suppressed anti-SRBC IgG in comparison to control group, however, the 158 
suppression was more by H2R- antagonist than H1R- antagonist. By day 7- post-I, the 159 
antibody titer was significantly high, which obtained a peak between days 14- to 21- 160 
post-I, and by day 28- post-I, it gradually fell down or maintained a plateau in the 161 
experimental groups (Fig. 3). More extensive evaluation revealed that anti-SRBC IgG 162 
raised steeply up to 14 days post-I, and then there was a significant decrease in H1R-163 
anatagonist (Pheniramine)- treated group, however, the H2R-antagonist (ranitidine)- 164 
treated, and control group (untreated) showed slight increase until 21 days and finally 165 
maintained a plateau. The results of ELISA, detecting the anti-SRBC IgG, are shown in 166 
Fig. 3. 167 
  168 
 169 
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DISCUSSION 171 
It is being documented in previous studies that in mice, B cell proliferation in response to 172 
anti-IgM is increased; however it is diminished in H1R-deficient mice. In H1R-deficient 173 
mice, antibody production against a T cell-independent antigen-TNP-ficoll is 174 
diminished5, and also in a further study antibody response to T cell-dependent antigens 175 
like ovalbumin (OVA) demonstrated a different pattern3. H1R-deficient mice produced 176 
high OVA-specific IgG1 and IgE as compared with wild type mice. In contrast, H2R-177 
deficient mice showed diminished serum levels of OVA-specific IgG3 and IgE in 178 
comparison to wild type mice and H1R-deficient mice. Thus H1R-deficient mice display 179 
both strong systemic T cell and efficient B cell responses to antigen18. 180 
In this study, we used H1R specific antagonist pheniramine to inhibit histamine binding 181 
to H1R, and H2R specific antagonist ranitidine for inhibition of histamine binding to 182 
H2R; both inhibitions demonstrated their effects on antibody response. Histamine 183 
receptor type 2 (H2R) antagonists have a beneficial effect on immunosuppression 184 
induced by trauma, blood transfusion and sepsis. This has been suggested that histamine 185 
receptor type 2 (H2R) antagonists exert their immunomodulatory effects via 186 
improvements in lymphocyte response19-21. The differential expression of histamine 187 
receptor type 1 (H1R) and histamine receptor type 2 (H2R) on lymphocytes (B-cells and 188 
T-cells) should result in distinct biochemical intracellular events triggered upon receptor 189 
stimulation. Therefore, we investigated the total serum antibody, IgM and IgG antibody 190 
generation profile against sheep red blood cells (SRBC), a T lymphocyte-dependent test 191 
antigen17 modulated by endogenous histamine (released from effector cells), H1R 192 
antagonist (pheniramine) and H2R antagonist (ranitidine). 193 
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 As the evaluation of a primary antibody response to a T-lymphocyte-dependent antigen 194 
(e.g., SRBC or keyhole limpet hemocyanin) is known as one of the most sensitive 195 
immune function tests following chemical exposures22, The T-cell-dependent antibody 196 
response assay is highly sensitive indicator of immunological integrity. Sheep red blood 197 
cells (SRBC) is used as the particular T-lymphocyte-dependent antigen, and this response 198 
requires the coordinated interaction of various immune system cells (antigen-presenting 199 
cells, T-lymphocytes, and B-lymphocytes)17. To provide exact evidence relating our 200 
investigations to in vivo immunoregulatory processes, we used healthy rabbits with and 201 
without H1R- and H2R-antagonists treatment. Here we demonstrate that H1R and H2R-202 
treated rabbits are characterized by a marked deviation of the immune response compared 203 
with control rabbits (non HRs antagonist treatment). The effect of histamine and 204 
differential histamine receptors (HRs) expression on B-lymphocytes (antibody producing 205 
cells) was analyzed by SRBC-specific T-cell-dependent antibody production in H1R- and 206 
H2R- antagonists treated, and non-treated rabbits (control group).  207 
In this study we demonstrated that the histamine, released from effector cells (mast cells 208 
and basophils) in vivo during inflammatory reactions, can influence a detectable antibody 209 
response to SRBC as early as day 7- post-I, which lasted until day 28- post-I in all 210 
groups. It must be emphasized here that, to the best of our knowledge, none of the earlier 211 
reports have demonstrated the anti-SRBC antibody profile over a span of study period, 212 
rather all previous reports have studied the anti-SRBC antibody concentrations at a single 213 
time period taking single blood samples from experimental animals. Pheniramine-treated 214 
rabbits had significantly (P≤ 0.05) more suppressed total serum anti-SRBC-antibody as 215 
compared to ranitidine-treated and control group. Whereas, ranitidine suppressed total 216 
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anti-SRBC-antibody levels at day’s 7- and 14- post-I, and enhanced total anti-SRBC-217 
antibody levels at day’s 21- and 28- post-I. On evaluating the differential IgM and IgG 218 
profiles affected by ranitidine, it was interestingly noticed that it suppressed the IgM at 219 
day 7- post-I whereas it enhanced anti-SRBC IgM at day’s 14-, 21-, and 28- post-I in 220 
comparison to controls. On the other hand, IgG remained suppressed during the whole 221 
study period, in comparison to controls, however, the suppression was to a lower extent 222 
when compared with Pheniramine. 223 
In nutshell, our findings to in vivo immunoregulatory processes, demonstrated that total 224 
antibody, total IgM and total IgG generation profile in pheniramine (H1R-antagonist)-225 
treated group is completely suppressed as compared to ranitidine (H2R-antagonist)-226 
treated and control group, while total antibody and total IgM in ranitidine (H2R-227 
antagonist)-treated group is suppressed initially and enhanced in a later phase in 228 
comparison to control group, and IgG profile remained suppressed in comparison to 229 
control group. These results demonstrate B-cell proliferation, in response to anti-IgM, is 230 
increased in H2R-antagonist treated rabbits and is diminished in H1R-antagonist treated 231 
rabbits, and that H1R-antagonist treated rabbits display diminished antibody production 232 
against a T cell-dependent antigen-SRBC as compared with H2R-antagonist treated and 233 
control rabbits. In conclusion, our results demonstrate that histamine receptor type 2 234 
(H2R)-antagonists have a dominant role on immunosuppression and in immunoregulation 235 
of humoral immune responses. Histamine receptor type 2 (H2R)-antagonists are mainly 236 
involved in B cell differentiation and proliferation over histamine receptor type 1 (H1R)-237 
antagonists. This is the first report studying the immunomodulatory profile in 238 
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experimental rabbits over a continued study period of 28 days pre- and post-239 
immunization. 240 
 241 
MATERIALS AND METHODS 242 
Experimental design 243 
To evaluate the systemic antibody response, New Zealand adult healthy rabbits of either 244 
sex weighing from 1-1.5 kg were divided into three treatment groups: group I was vehicle 245 
treated and immunized as a positive control (n=6), group II was histamine H1-receptor 246 
antagonist treated and immunized (n=6), group III was histamine H2-receptor antagonist 247 
treated and immunized (n=6). The animals were maintained in well-maintained animal 248 
facility at central animal house, J. N. Medical College, Aligarh Muslim University, 249 
Aligarh, in the Bioresources unit under a 12h light/dark cycle, temperature (22±2ºC) and 250 
were allowed free access to standard laboratory diet including green vegetables and tap 251 
water until experimentation. All studies were carried out during the light cycle and all 252 
studies were approved by the Institutional Animal ethical committee. Each animal was 253 
used only once. 254 
 255 
Materials 256 
All materials were obtained from the following manufacturers: Anti-rabbit-IgG-257 
horseradish peroxidase conjugate from Sigma (USA), tetramethyl benzidine (TMB) and 258 
TMB diluent from J. Mitra and Co. (India), Polystyrene MaxiSorp microtitre flat and 259 
round bottom ELISA plates from NUNC (Denmark), Glutaraldehyde solution from 260 
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Central Drug House (India), 2-mercaptoethanol (2-ME) from Merck KGaA, Darmstadt 261 
(Germany). All chemicals were of analytical grade.                                 262 
 263 
Drugs 264 
The following drugs were used: Avil® (Pheniramine maleate) in injection I.P. by 265 
Unimark Remedies, India and Rantac® (Ranitidine hydrochloride) in injection I.P. by J. 266 
B. Chemicals and pharmaceuticals, India. All doses refered to the weight of the salts 267 
used. 268 
Dose 269 
Histamine H1-receptor antagonist (Pheniramine maleate) was 5mg/0.22ml/kg/day and 270 
histamine H2-receptor antagonist (Ranitidine hydrochloride) 10mg/0.4ml/kg/day, and 271 
wereadministered intramuscularly, starting from three days prior to immunization until 7 272 
days after immunization. 273 
 274 
Antigen 275 
Sheep blood diluted 1:1 in Alsevier’s solution was obtained from Department of 276 
Microbiology, J. N. Medical College, A.M.U., Aligarh, and washed with PBS (10 mM 277 
sodium phosphate buffer containing 150 mM Nacl, pH-7.4) thrice, and finally the 278 
concentration was adjusted to 5% (1 × 109 cells/ml) in PBS for immunization before use. 279 
 280 
Immunization of Rabbit 281 
The rabbits in all groups (I, II, and III) were immunized intravenously  with 1ml of 5% (1 282 
× 109 cells/ml) sheep red blood cells (SRBC) in PBS.  283 
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 284 
 285 
 286 
Sample collection 287 
To determine the systemic antibody response, blood samples were collected from rabbits 288 
via the marginal ear vein on the day of immunization (day 0), prior to immunization, as 289 
well as on days 7th, 14th, 21st and 28th post immunization. Blood samples were kept at 290 
room temperature for 2h and then at 4ºC overnight. Blood samples were centrifuged for 291 
10 minutes at 580×g, and serum was isolated and heated at 56ºC for 30 minutes to 292 
inactivate complement proteins and stored in aliquots at -20ºC till tested with sodium 293 
azide as preservative. 294 
Serological Analysis 295 
Hemagglutination Assay 296 
To determine the antibody response to sheep red blood cells (SRBC), a direct 297 
hemagglutination technique16 was used with some modifications. Briefly, 100µL of PBS 298 
was dispensed into each well of a round bottomed 96-well microplate. Serum sample 299 
(100µL) were then added using serial two-fold dilutions (1:2, 1:4, 1:8, 1:16, 1:32…) in 300 
the wells from columns 2 to 12. The first column (PBS only) of wells was considered 301 
blank. Then, 100µL of 2% sheep red blood cells (SRBC) in PBS was added to all wells to 302 
make a final volume of 200µL. Subsequently, the plates were shaken for 1 minutes and 303 
incubated at 37ºC for 1h, and then overnight at 4ºC to determine agglutination titres. A 304 
positive result was recorded when at least 50% SRBC agglutination was observed. To 305 
measure anti-SRBC IgM and IgG antibody, serum sample were treated with 0.2M 2-306 
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mercaptoethanol (2-ME) for 1h at 37ºC. This treatment inactivates IgM antibody, and as a 307 
result, hemagglutination observed after treatment with 2-ME is due mostly to the 308 
presence of IgG antibody. The difference between total antibodies and IgG antibody titres 309 
were taken as the titres of IgM antibody. 310 
 311 
ELISA Using Whole SRBC  312 
To determine the SRBC-specific-immunoglobulin-G (IgG) response, the whole sheep red 313 
blood cells (SRBC)-enzyme linked immunosorbent assay (ELISA) was also carried out 314 
on polystryrene plates according to the method described by Koganei et al.17 with some 315 
modifications. Briefly, polystryrene maxiSorp immunoplates were coated with SRBC 316 
suspension (5 × 106/100 µL PBS [10 mM sodium phosphate buffer containing 150 mM 317 
Nacl, pH-7.4]). The plates were held overnight at 4ºC. Each sample was coated in 318 
duplicate and half of the plates served as control devoid of only antigen coating. Without 319 
disturbing the cell layer, 20 µL of 1.8% glutaraldehyde solution was then gently added to 320 
plates inoculated with SRBC and the plates were held at 25ºC 30 min. Unbound SRBC 321 
was washed four times with 200 µL of PBS and non-specific binding sites were blocked 322 
with 1% fat-free milk in PBS for 2 hr at 37ºC. After incubation, the plates were washed 323 
four times with 200 µL of PBS. Each rabbit serum diluted 1:100 in PBS (100 µL well-1) 324 
was adsorbed for 1.5 hr at 37ºC, and then overnight at 4ºC. The secondary antibody, HRP-325 
conjugated anti-rabbit IgG, was then added to each well and the plate incubated at 37ºC 326 
for 1 hr. TMB substrate was then added to each well and the plates were incubated at 327 
25ºC 1 hr. The absorbance (A) was determined at 405 nm on an automatic microplate 328 
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reader. Each rabbit serum sample was run in duplicate. The control wells were treated 329 
similarly but were devoid of antigen. Results were expressed as a mean of Atest-Acontrol.  330 
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Figure 1. Anti-SRBC-antibody production in control (not treated with HR-antagonists) 359 
(▲), H1R-antagonist treated (■) and H2R-antagonist treated (o) rabbits. Rabbits were 360 
immunized intravenously by SRBC at day 0. Anti-SRBC-antibody was detected from 361 
serum samples obtained at day 0 (pre-immunization) and days 7, 14, 21, and 28 (post-362 
immunization). Anti-SRBC-antibody was determined by a direct haemagglutination 363 
assay. The results are expressed as –log2 titre and demonstrate mean ± s.d. of each 364 
experiment with six rabbits. 365 
 366 
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Figure 2. Anti-SRBC IgM production in control (not treated with HR-antagonists) (▲), 372 
H1R-antagonist treated (■) and H2R-antagonist treated (o) rabbits. Rabbits were 373 
immunized intravenously by SRBC at day 0. Anti-SRBC IgM titer was the difference 374 
between total antibody and IgG titers detected from serum samples obtained at day 0 375 
(pre-immunization) and days 7, 14, 21, and 28 (post-immunization). Anti-SRBC IgM was 376 
determined by a direct haemagglutination assay with and without 2ME treatment. The 377 
results are expressed as –log2 titer and demonstrate mean ± s.d. of each experiment with 378 
six rabbits. 379 
 380 
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Figure 3. SRBC-specific IgG production in control (not treated with HR-antagonists) 388 
(▲), H1R-antagonist (pheniramine) treated (■) and H2R-antagonist (ranitidine) treated 389 
(o) rabbits. Rabbits were immunized intravenously by SRBC at day 0. SRBC-specific 390 
IgG was detected from serum samples obtained at day 0 (pre-immunization) and days 7, 391 
14, 21, and 28 (post-immunization). SRBC-specific IgG was determined by whole 392 
SRBC-ELISA in duplicates 1:100 diluted serum. The results demonstrate mean ± s.d. of 393 
each experiment with six rabbits. 394 
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